市場調査レポート

商品コード

1140281

統合失調症治療薬市場：治療クラス別、治療法別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Schizophrenia Drugs Market By Therapeutic Class, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年07月01日 | 発行: Allied Market Research

| ページ情報: 英文 220 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,989円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 900,412円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,508,544円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

統合失調症治療薬の世界市場は、2021年に71億6040万米ドル、2031年には125億3320万米ドルに達すると予測され、2022年から2031年までのCAGRは5.8%を記録しています。

統合失調症は、現実を異常に解釈してしまう深刻な精神疾患です。統合失調症は、幻覚や妄想、日常生活に支障をきたすほど乱れた思考や行動などを引き起こし、身体的な障害をもたらすことがあります。

身体的、遺伝的、心理的、環境的な様々な要因が引き金となり発症する可能性があります。ストレスの多いライフスタイルの増加は、市場の成長を促進します。また、老年人口の急増が市場の成長を後押ししています。例えば、世界保健機関（WHO）によると、2050年には60歳以上の高齢者人口が21億人に達すると推定されています。このような高齢者層は、遅発性統合失調症になりやすいと言われています。そのため、ストレスの多いライフスタイルや精神的プレッシャーの増加が、市場の成長を後押ししています。

さらに、オピオイドやアンフェタミンなどの薬物の長期消費は、妄想や幻覚などの統合失調症の症状の原因となっています。また、大麻、コカイン、LSDの違法消費は、統合失調症の引き金となる可能性があります。さらに、世界的に統合失調症の有病率が上昇していることも、市場の成長を後押ししています。例えば、2022年1月、世界保健機関（WHO）によると、統合失調症は世界で約2,400万人、300人に1人（0.32％）が罹患していると言われています。このように、薬物乱用の発生率の上昇と統合失調症の有病率の増加が、市場の成長を後押ししています。

さらに、統合失調症治療薬の開発のための研究開発活動の増加、米国食品医薬品局（USFDA）の承認の上昇、主要企業による市場での新規製品の上市は、市場の成長を後押しします。例えば、2021年9月、ジョンソン・エンド・ジョンソンの子会社であるヤンセンファーマは、米国食品医薬品局（FDA）より、成人の統合失調症治療薬として初で唯一の年2回の注射剤である長時間作用型非定型抗精神病薬インベガ・ハフィーラ（6ヶ月分パリペリドン・パルミテート）の認可を取得しました。また、精神科診療所の増加や医療インフラの整備も市場の成長に寄与しています。しかし、適切なヘルスケアインフラの欠如や治療へのアドヒアランスの低さが、市場の成長を阻害する可能性があります。

概要
- 市場規模および予測
第二世代
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別分析
第三世代
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章統合失調症治療薬市場：治療法別

概要
- 市場規模および予測
経口
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
注射剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章統合失調症治療薬市場：流通チャネル別

概要
- 市場規模・予測
病院薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
小売薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
オンライン薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章統合失調症治療薬市場：地域別

概要
- 市場規模および予測
北米
- 主要動向と機会
- 北米市場規模・予測：治療薬クラス別
- 北米市場規模・予測：治療法別
- 北米市場規模・予測：流通チャネル別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主要動向と機会
- 欧州市場規模・予測：治療クラス別
- 欧州市場規模・予測：治療法別
- 欧州市場規模・予測：流通チャネル別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他の欧州地域
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：治療クラス別
- アジア太平洋地域の市場規模・予測：治療法別
- アジア太平洋地域の市場規模・予測：流通チャネル別
- アジア太平洋地域の市場規模・予測：国別
  - 中国
  - 日本
  - インド
  - オーストラリア
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：治療クラス別
- LAMEAの市場規模・予測：治療法別
- LAMEAの市場規模・予測：流通チャネル別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

Pfizer Inc.
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck KGAA
Minerva Neurosciences
Novartis AG
Reliance
Sumitomo Dainippon
Takeda Pharmaceuticals
Vanda Pharmaceuticals
Alkermes

図表

LIST OF TABLES

TABLE 1. GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 2. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR SECOND GENERATION, BY REGION, 2021-2031 ($MILLION)
TABLE 3. SCHIZOPHRENIA DRUGS MARKET FOR SECOND GENERATION BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR THIRD GENERATION, BY REGION, 2021-2031 ($MILLION)
TABLE 5. SCHIZOPHRENIA DRUGS MARKET FOR THIRD GENERATION BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR OTHER, BY REGION, 2021-2031 ($MILLION)
TABLE 7. SCHIZOPHRENIA DRUGS MARKET FOR OTHER BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 9. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 10. SCHIZOPHRENIA DRUGS MARKET FOR ORAL BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
TABLE 12. SCHIZOPHRENIA DRUGS MARKET FOR INJECTABLE BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 14. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 15. SCHIZOPHRENIA DRUGS MARKET FOR HOSPITAL PHARMACIES BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 17. SCHIZOPHRENIA DRUGS MARKET FOR RETAIL PHARMACIES BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. SCHIZOPHRENIA DRUGS MARKET SIZE, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 19. SCHIZOPHRENIA DRUGS MARKET FOR ONLINE PHARMACIES BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. SCHIZOPHRENIA DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 21. NORTH AMERICA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 22. NORTH AMERICA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 23. NORTH AMERICA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA SCHIZOPHRENIA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. U.S. SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 26. U.S. SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 27. U.S. SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 28. CANADA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 29. CANADA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 30. CANADA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 31. MEXICO SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 32. MEXICO SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 33. MEXICO SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. EUROPE SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 35. EUROPE SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 36. EUROPE SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. EUROPE SCHIZOPHRENIA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 38. GERMANY SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 39. GERMANY SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 40. GERMANY SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. FRANCE SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 42. FRANCE SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 43. FRANCE SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. U.K. SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 45. U.K. SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 46. U.K. SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. ITALY SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 48. ITALY SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 49. ITALY SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 50. SPAIN SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 51. SPAIN SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 52. SPAIN SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 53. REST OF EUROPE SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 54. REST OF EUROPE SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 55. REST OF EUROPE SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 56. ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 57. ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 58. ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 60. CHINA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 61. CHINA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 62. CHINA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 63. JAPAN SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 64. JAPAN SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 65. JAPAN SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. INDIA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 67. INDIA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 68. INDIA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. AUSTRALIA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 70. AUSTRALIA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 71. AUSTRALIA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 72. SOUTH KOREA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 73. SOUTH KOREA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 74. SOUTH KOREA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 77. REST OF ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. LAMEA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 79. LAMEA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 80. LAMEA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. LAMEA SCHIZOPHRENIA DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 82. BRAZIL SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 83. BRAZIL SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 84. BRAZIL SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 85. SAUDI ARABIA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 86. SAUDI ARABIA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 87. SAUDI ARABIA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 88. SOUTH AFRICA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 89. SOUTH AFRICA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 90. SOUTH AFRICA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 91. REST OF LAMEA SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS, 2021-2031 ($MILLION)
TABLE 92. REST OF LAMEA SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 93. REST OF LAMEA SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 94.PFIZER INC.: COMPANY SNAPSHOT
TABLE 95.PFIZER INC.: OPERATING SEGMENTS
TABLE 96.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 97.PFIZER INC.: NET SALES,
TABLE 98.PFIZER INC.: KEY STRATERGIES
TABLE 99.ABBVIE: COMPANY SNAPSHOT
TABLE 100.ABBVIE: OPERATING SEGMENTS
TABLE 101.ABBVIE: PRODUCT PORTFOLIO
TABLE 102.ABBVIE: NET SALES,
TABLE 103.ABBVIE: KEY STRATERGIES
TABLE 104.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 105.ASTRAZENECA: OPERATING SEGMENTS
TABLE 106.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 107.ASTRAZENECA: NET SALES,
TABLE 108.ASTRAZENECA: KEY STRATERGIES
TABLE 109.BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 110.BRISTOL MYERS SQUIBB: OPERATING SEGMENTS
TABLE 111.BRISTOL MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 112.BRISTOL MYERS SQUIBB: NET SALES,
TABLE 113.BRISTOL MYERS SQUIBB: KEY STRATERGIES
TABLE 114.ELI LILLY: COMPANY SNAPSHOT
TABLE 115.ELI LILLY: OPERATING SEGMENTS
TABLE 116.ELI LILLY: PRODUCT PORTFOLIO
TABLE 117.ELI LILLY: NET SALES,
TABLE 118.ELI LILLY: KEY STRATERGIES
TABLE 119.GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 120.GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 121.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 122.GLAXOSMITHKLINE: NET SALES,
TABLE 123.GLAXOSMITHKLINE: KEY STRATERGIES
TABLE 124.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 125.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 126.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 127.JOHNSON & JOHNSON: NET SALES,
TABLE 128.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 129.MERCK KGAA: COMPANY SNAPSHOT
TABLE 130.MERCK KGAA: OPERATING SEGMENTS
TABLE 131.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 132.MERCK KGAA: NET SALES,
TABLE 133.MERCK KGAA: KEY STRATERGIES
TABLE 134.MINERVA NEUROSCIENCES: COMPANY SNAPSHOT
TABLE 135.MINERVA NEUROSCIENCES: OPERATING SEGMENTS
TABLE 136.MINERVA NEUROSCIENCES: PRODUCT PORTFOLIO
TABLE 137.MINERVA NEUROSCIENCES: NET SALES,
TABLE 138.MINERVA NEUROSCIENCES: KEY STRATERGIES
TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 142.NOVARTIS AG: NET SALES,
TABLE 143.NOVARTIS AG: KEY STRATERGIES
TABLE 144.RELIANCE: COMPANY SNAPSHOT
TABLE 145.RELIANCE: OPERATING SEGMENTS
TABLE 146.RELIANCE: PRODUCT PORTFOLIO
TABLE 147.RELIANCE: NET SALES,
TABLE 148.RELIANCE: KEY STRATERGIES
TABLE 149.SUMITOMO DAINIPPON: COMPANY SNAPSHOT
TABLE 150.SUMITOMO DAINIPPON: OPERATING SEGMENTS
TABLE 151.SUMITOMO DAINIPPON: PRODUCT PORTFOLIO
TABLE 152.SUMITOMO DAINIPPON: NET SALES,
TABLE 153.SUMITOMO DAINIPPON: KEY STRATERGIES
TABLE 154.TAKEDA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 155.TAKEDA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 156.TAKEDA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 157.TAKEDA PHARMACEUTICALS: NET SALES,
TABLE 158.TAKEDA PHARMACEUTICALS: KEY STRATERGIES
TABLE 159.VANDA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 160.VANDA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 161.VANDA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 162.VANDA PHARMACEUTICALS: NET SALES,
TABLE 163.VANDA PHARMACEUTICALS: KEY STRATERGIES
TABLE 164.ALKERMES: COMPANY SNAPSHOT
TABLE 165.ALKERMES: OPERATING SEGMENTS
TABLE 166.ALKERMES: PRODUCT PORTFOLIO
TABLE 167.ALKERMES: NET SALES,
TABLE 168.ALKERMES: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.SCHIZOPHRENIA DRUGS MARKET SEGMENTATION
FIGURE 2.SCHIZOPHRENIA DRUGS MARKET,2021-2031
FIGURE 3.SCHIZOPHRENIA DRUGS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.SCHIZOPHRENIA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.SCHIZOPHRENIA DRUGS MARKET,BY THERAPEUTIC CLASS,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF SECOND GENERATION SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF THIRD GENERATION SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHER SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
FIGURE 16.SCHIZOPHRENIA DRUGS MARKET,BY TREATMENT,2021(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ORAL SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF INJECTABLE SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
FIGURE 19.SCHIZOPHRENIA DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES SCHIZOPHRENIA DRUGS MARKET,2021-2031(%)
FIGURE 23.SCHIZOPHRENIA DRUGS MARKET BY REGION,2021
FIGURE 24.U.S. SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 25.CANADA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 26.MEXICO SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 27.GERMANY SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 28.FRANCE SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 29.U.K. SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 30.ITALY SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 31.SPAIN SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 32.REST OF EUROPE SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 33.CHINA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 34.JAPAN SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 35.INDIA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 36.AUSTRALIA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 37.SOUTH KOREA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 38.REST OF ASIA-PACIFIC SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 39.BRAZIL SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 40.SAUDI ARABIA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 41.SOUTH AFRICA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 42.REST OF LAMEA SCHIZOPHRENIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47.COMPETITIVE DASHBOARD
FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 49.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 50.ABBVIE.: NET SALES ,($MILLION)
FIGURE 51.ASTRAZENECA.: NET SALES ,($MILLION)
FIGURE 52.BRISTOL MYERS SQUIBB.: NET SALES ,($MILLION)
FIGURE 53.ELI LILLY.: NET SALES ,($MILLION)
FIGURE 54.GLAXOSMITHKLINE.: NET SALES ,($MILLION)
FIGURE 55.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
FIGURE 56.MERCK KGAA.: NET SALES ,($MILLION)
FIGURE 57.MINERVA NEUROSCIENCES.: NET SALES ,($MILLION)
FIGURE 58.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 59.RELIANCE.: NET SALES ,($MILLION)
FIGURE 60.SUMITOMO DAINIPPON.: NET SALES ,($MILLION)
FIGURE 61.TAKEDA PHARMACEUTICALS.: NET SALES ,($MILLION)
FIGURE 62.VANDA PHARMACEUTICALS.: NET SALES ,($MILLION)
FIGURE 63.ALKERMES.: NET SALES ,($MILLION)

Product Code: A17082

The global schizophrenia drugs market was valued at $7,160.4 million in 2021, and is projected to reach $12,533.2 million by 2031, registering a CAGR of 5.8% from 2022 to 2031.

Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It may result in some combination of hallucinations, delusions, and extremely disordered thinking & behavior that impairs daily functioning, and can be disabling.

It can be triggered by various physical, genetic, psychological and environmental factors. The increase in stressful lifestyle drives the growth of market. In addition, surge in geriatric population drives the growth of market. For instance, according to world health organization (WHO), in 2050, the world's population of people aged 60 years and older is estimated to reach 2.1 billion. The old age population are prone to late-onset schizophrenia. Thus, rise in stressful lifestyle and mental pressure drives the growth of market.

Furthermore, long term consumption of drugs such as opioids and amphetamines are responsible for some schizophrenia symptoms such as delusions and hallucinations. In addition, illegal consumption of cannabis, cocaine, and LSD may trigger schizophrenia. Furthermore, rise in prevalence of schizophrenia globally, drives the growth of market. For instance, in January 2022, according to world health organization (WHO), schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. Thus, rise in incidences of drug abuse and increase in prevalence of schizophrenia drives the growth of market.

Moreover, the increase in R&D activities for development of Schizophrenia Drugs, rise in United States food and drug administration (USFDA) approvals, and novel product launches in market by key players boost the market growth. For instance, in September 2021, The Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, received U.S. food and drug administration (FDA), long-acting atypical antipsychotic INVEGA HAFYERA (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Furthermore, the rise in number of mental disorder clinics and improvement in healthcare infrastructure further contribute in the market growth. However, the lack of appropriate healthcare infrastructure and dearth of adherence to therapy may hinder the growth of market.

The schizophrenia drugs market is segmented on the basis of therapeutic class, treatment, distribution channel, and region. By therapeutic class, the market is classified into second-generation, third-generation, and others. Depending on treatment, the market is divided into oral and injectable. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include: Pfizer, AbbVie, Alkermes, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck KGAA, Minerva Neurosciences, Novartis AG, Reliance pharmaceuticals, Sumitomo Dainippon, Takeda Pharmaceuticals, Vanda Pharmaceuticals, Viatris (Mylan NV), and Zydus Cadila

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the schizophrenia drugs market analysis from 2021 to 2031 to identify the prevailing schizophrenia drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the schizophrenia drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global schizophrenia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Treatment

Oral
Injectable

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Therapeutic Class

Second Generation
Third Generation
Other

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Pfizer Inc.
- AbbVie
- AstraZeneca
- Bristol Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Merck KGAA
- Minerva Neurosciences
- Novartis AG
- Reliance
- Sumitomo Dainippon
- Takeda Pharmaceuticals
- Vanda Pharmaceuticals
- Alkermes

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Second Generation
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Third Generation
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Other
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country

CHAPTER 5: SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Oral
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Injectable
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country

CHAPTER 6: SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: SCHIZOPHRENIA DRUGS MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Therapeutic Class
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Therapeutic Class
  - 7.2.5.1.2 Market size and forecast, by Treatment
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Therapeutic Class
  - 7.2.5.2.2 Market size and forecast, by Treatment
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Therapeutic Class
  - 7.2.5.3.2 Market size and forecast, by Treatment
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Therapeutic Class
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Therapeutic Class
  - 7.3.5.1.2 Market size and forecast, by Treatment
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Therapeutic Class
  - 7.3.5.2.2 Market size and forecast, by Treatment
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 U.K.
  - 7.3.5.3.1 Market size and forecast, by Therapeutic Class
  - 7.3.5.3.2 Market size and forecast, by Treatment
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Therapeutic Class
  - 7.3.5.4.2 Market size and forecast, by Treatment
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Therapeutic Class
  - 7.3.5.5.2 Market size and forecast, by Treatment
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Therapeutic Class
  - 7.3.5.6.2 Market size and forecast, by Treatment
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Therapeutic Class
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 China
  - 7.4.5.1.1 Market size and forecast, by Therapeutic Class
  - 7.4.5.1.2 Market size and forecast, by Treatment
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 Japan
  - 7.4.5.2.1 Market size and forecast, by Therapeutic Class
  - 7.4.5.2.2 Market size and forecast, by Treatment
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Therapeutic Class
  - 7.4.5.3.2 Market size and forecast, by Treatment
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Therapeutic Class
  - 7.4.5.4.2 Market size and forecast, by Treatment
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Therapeutic Class
  - 7.4.5.5.2 Market size and forecast, by Treatment
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Therapeutic Class
  - 7.4.5.6.2 Market size and forecast, by Treatment
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Therapeutic Class
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Therapeutic Class
  - 7.5.5.1.2 Market size and forecast, by Treatment
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Therapeutic Class
  - 7.5.5.2.2 Market size and forecast, by Treatment
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Therapeutic Class
  - 7.5.5.3.2 Market size and forecast, by Treatment
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Therapeutic Class
  - 7.5.5.4.2 Market size and forecast, by Treatment
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Pfizer Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 AbbVie
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 AstraZeneca
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Bristol Myers Squibb
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Eli Lilly
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 GlaxoSmithKline
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Johnson & Johnson
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Merck KGAA
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Minerva Neurosciences
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
9.11 Reliance
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
9.12 Sumitomo Dainippon
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
9.13 Takeda Pharmaceuticals
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
9.14 Vanda Pharmaceuticals
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
9.15 Alkermes
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments

統合失調症治療薬市場：治療クラス別、治療法別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Schizophrenia Drugs Market By Therapeutic Class, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章統合失調症治療薬市場：治療薬クラス別

第5章統合失調症治療薬市場：治療法別

第6章統合失調症治療薬市場：流通チャネル別

第7章統合失調症治療薬市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS

CHAPTER 5: SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT

CHAPTER 6: SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: SCHIZOPHRENIA DRUGS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

統合失調症治療薬市場：治療クラス別、治療法別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Schizophrenia Drugs Market By Therapeutic Class, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 統合失調症治療薬市場：治療薬クラス別

第5章 統合失調症治療薬市場：治療法別

第6章 統合失調症治療薬市場：流通チャネル別

第7章 統合失調症治療薬市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS

CHAPTER 5: SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT

CHAPTER 6: SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: SCHIZOPHRENIA DRUGS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章統合失調症治療薬市場：治療薬クラス別

第5章統合失調症治療薬市場：治療法別

第6章統合失調症治療薬市場：流通チャネル別

第7章統合失調症治療薬市場：地域別

第8章企業情勢

第9章企業プロファイル